I am grateful for the support of Dr Brian Hindley and Dr Razeen Sally, of the London School of Economics, whose guidance, encouragement and wisdom were always available to me. I wish to thank the intellectual property directors of pharmaceutical companies and associations and the various government officials who openly and candidly provided me with information regarding the realities of intellectual property policy-making.